[The "COVID-19 Bonus" almost disappeared, and Pfizer's reset revenue guidance caused the stock price to collapse] On Wednesday, the US Eastern Time, Pfizer announced that its revenue in 2024 might be about 5 billion dollars lower than Wall Street's expectations. This caused its stock price to plummet by over 8%, reaching a new low since 2014. The COVID-19 has brought record sales to Pfizer, and with the end of the epidemic, Pfizer's share price has also been returned to its original form.